<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-041287</identifier>
<setSpec>0001-7310</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Celecoxib-induced aquagenic keratoderma</dc:title>
<dc:description xml:lang="en">Aquagenic keratoderma is an infrequent condition characterized by translucent, smooth-surfaced papules and plaques and prominent eccrine ducts. It is limited to the palms and appears or becomes more pronounced after exposure to water. Histopathologically, hyperkeratosis and dilation of the eccrine ducts are seen. This condition has been described in adolescents and young women. We present the case of a 31-year-old woman with rheumatoid arthritis who had begun treatment with celecoxib one month before the onset of her cutaneous symptoms. Similar changes have been described in association with cystic fibrosis, and a case induced by rofecoxib has also been reported. Higher levels of sodium in the skin associated with celecoxib could increase the keratin's ability to take in water, and this may cause the clinical symptoms</dc:description>
<dc:creator>Vildósola, Susana</dc:creator>
<dc:creator>Ugalde, Aitziber</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La queratodermia acuagénica es un cuadro poco frecuente caracterizado por pápulas y placas translúcidas con una superficie lisa y ductos ecrinos prominentes, limitado a palmas, que aparece o se hace más pronunciado tras la exposición del agua. Histopatológicamente se aprecia hiperqueratosis y dilatación de los ductos ecrinos. Este cuadro se ha descrito en adolescentes y mujeres jóvenes. Presentamos el caso de una mujer de 31 años de edad con una artritis reumatoide que había comenzado tratamiento con celecoxib un mes antes del inicio de sus síntomas cutáneos. Cambios similares se han descrito en asociación con fribosis quística y está descrito un caso inducido por rofecoxib. El incremento de sodio en la piel asociado a la toma de celecoxib podría causar un incremento en la capacidad de captación de agua por la queratina y ser el causante del cuadro clínico</dc:description>
<dc:source>Actas Dermosifiliogr;96(8): 537-539, oct. 2005. ilus</dc:source>
<dc:identifier>ibc-041287</dc:identifier>
<dc:title xml:lang="es">Queratodermia acuagénica inducida por celecoxib</dc:title>
<dc:subject>^d906^s28898</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d30914^s22067</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d30695^s22012</dc:subject>
<dc:subject>^d7802^s22020</dc:subject>
<dc:subject>^d30914^s22016</dc:subject>
<dc:subject>^d28027^s22073</dc:subject>
<dc:subject>^d7126^s22012</dc:subject>
<dc:subject>^d7802^s22068</dc:subject>
<dc:subject>^d30914^s22057</dc:subject>
<dc:subject>^d32969^s22073</dc:subject>
<dc:subject>^d906^s22020</dc:subject>
<dc:type>article</dc:type>
<dc:date>200510</dc:date>
</metadata>
</record>
</ibecs-document>
